Chronic Disease Management to Enhance Medication Adherence Trajectories in Long‐Term Survivors of Stroke: A Population‐Based Cohort Study
Pharmacoepidemiology and Drug Safety · 2025
DOI: 10.1002/pds.70148 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Lachlan L Dalli und 13 weiteren Autor:innen. Beteiligte Einrichtung: Stroke and Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia. Hauptthemen laut MEDLINE: Stroke, Ischemic Attack, Transient, Disease Management, Medication Adherence. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Heart Foundation of Australia, National Health and Medical Research Council.
Themen: Schlaganfall
Abstract (Originalsprache)
Purpose
Although chronic disease management (CDM) has been reported to improve medication adherence after stroke or transient ischaemic attack (TIA), the impact on specific patterns of medication adherence is unclear. We aimed to evaluate the population effect of receiving a CDM claim on trajectories of medication adherence in long‐term survivors of stroke/TIA.
Methods
A cohort study was undertaken using observational data from PRECISE (42 Australian Stroke Clinical Registry hospitals [Victoria and Queensland; 2012–2015] linked with medication dispensing and primary care claims). Community‐dwelling adults with ≥ 1 primary care visit were included. The exposure was a CDM claim (versus no claim) in primary care within 7–18 months post‐stroke/TIA. Medication adherence (antihypertensive, antithrombotic, lipid‐lowering) was assessed between 19 and 30 months post‐stroke/TIA, using group‐based trajectory models. Average treatment effects were estimated using multi‐level logistic regression with inverse probability treatment weights.
Results
Among 11 580 survivors of stroke/TIA (median age 70 years, 42% female; 45% with CDM claim), four distinct adherence patterns were identified: near‐perfect adherence, high adherence, declining adherence, and non‐use. After adjustment, having a CDM claim (vs no claim) promoted near‐perfect adherence (odds ratio [OR]: 1.16 [95% CI 1.08–1.25]) for antithrombotic medications. Whereas, having a CDM claim (vs no CDM claim) promoted high adherence for antihypertensive (OR: 1.33 [95% CI 1.24–1.44]) or lipid‐lowering (OR: 1.26 [95% CI 1.16–1.37]) medications. The odds of non‐use were also reduced by 17%–23% in those with (vs without) a CDM claim.
Conclusions
CDM claims were associated with favourable trajectories of medication adherence in long‐term survivors of stroke/TIA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stroke and Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.
- Stroke Division, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
- Department of Medicine, Peninsula Clinical School, School of Translational Medicine, Monash University, Frankston, Victoria, Australia.
- National Centre for Healthy Ageing, Peninsula Clinical School, School of Translational Medicine, Frankston, Victoria, Australia.
- Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia.
- Department of Medicine, St Vincent's Hospital, University of Melbourne, Fitzroy, Victoria, Australia.
ORCID-Profile: Lachlan L Dalli, Monique F Kilkenny, Muideen T Olaiya, David Ung, Joosup Kim, Leonid Churilov, Dominique A Cadilhac, Amanda G Thrift, Mark R Nelson, Natasha A Lannin, Rebecca Barnden, Velandai Srikanth, Nadine E Andrew
Förderung
- National Heart Foundation of Australia
- National Health and Medical Research Council
Zitieren
APA
Dalli, L. L., Kilkenny, M. F., Olaiya, M. T., Ung, D., Kim, J., Churilov, L., Cadilhac, D. A., Sundararajan, V., Thrift, A. G., Nelson, M. R., Lannin, N. A., Barnden, R., Srikanth, V., & Andrew, N. E. (2025). Chronic Disease Management to Enhance Medication Adherence Trajectories in Long‐Term Survivors of Stroke: A Population‐Based Cohort Study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70148
Vancouver
Dalli LL, Kilkenny MF, Olaiya MT, Ung D, Kim J, Churilov L, et al. Chronic Disease Management to Enhance Medication Adherence Trajectories in Long‐Term Survivors of Stroke: A Population‐Based Cohort Study. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70148
BibTeX
@article{Dalli2025,
author = {Dalli, Lachlan L and Kilkenny, Monique F and Olaiya, Muideen T and Ung, David and Kim, Joosup and Churilov, Leonid and Cadilhac, Dominique A and Sundararajan, Vijaya and Thrift, Amanda G and Nelson, Mark R and Lannin, Natasha A and Barnden, Rebecca and Srikanth, Velandai and Andrew, Nadine E},
title = {Chronic Disease Management to Enhance Medication Adherence Trajectories in Long‐Term Survivors of Stroke: A Population‐Based Cohort Study},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
doi = {10.1002/pds.70148}
}
EUVIMED